Heartflow, Inc. develops AI-enabled software for non-invasive detection and management of coronary artery disease. Its updates center on the Heartflow Platform and related analyses, including Heartflow FFRCT Analysis, Heartflow Plaque Analysis and Heartflow Roadmap Analysis, which use coronary CT imaging and software-based interpretation to support cardiovascular care.
Recurring news includes quarterly results, account adoption, payer coverage and reimbursement for Plaque Analysis, clinical evidence presented at cardiology meetings, patient registries such as GAMEFILM and NAVIGATE-PCI, investor conference activity, intellectual property enforcement and additions to Heartflow’s product platform such as PCI Navigator.
Heartflow (NASDAQ: HTFL), an AI technology company focused on coronary artery disease (CAD), has announced the pricing of its upsized IPO. The company is offering 16,666,667 shares at $19.00 per share, expecting to raise approximately $316.7 million in gross proceeds.
Trading will commence on August 8, 2025, on the Nasdaq Global Select Market. The underwriters have a 30-day option to purchase up to 2.5 million additional shares. The IPO is expected to close on August 11, 2025, with J.P. Morgan, Morgan Stanley, and Piper Sandler serving as joint book-running managers.
Heartflow (NYSE:HTFL) announced that UnitedHealthcare, the largest commercial insurer in the United States, will provide nationwide coverage for its AI-enabled Heartflow Plaque Analysis across all business lines. The coverage, effective October 1, 2025, will include Commercial, Medicare Advantage, and Community plans.
The FDA-cleared technology, showing 95% agreement with gold standard IVUS, helps diagnose and manage coronary artery disease (CAD). Clinical outcomes from the DECIDE registry demonstrated that management changes guided by Heartflow Plaque Analysis resulted in an average LDL cholesterol decrease of 18.7mg/dL, associated with a 15% reduction in cardiac event risk.